CeQur announced today that it closed a $120 million financing round to support its wearable insulin delivery technology.

Beta Bionics announced today that it filed a registration statement with the SEC relating to a proposed initial public ...

PreEvnt recently announced plans to introduce Isaac, its non-invasive alert device for monitoring blood glucose levels.

Left, the Dexcom G7 CGM. Right, the Abbott FreeStyle Libre 2. [Images from Dexcom and Abbott] The Unified Patent Court in Paris sided with Abbott (NYSE:ABT) following a CGM patent infringement claim ...

Left, the Dexcom G7 CGM. Right, the Abbott FreeStyle Libre 2. [Images from Dexcom and Abbott] Abbott (NYSE:ABT) announced today that it reached an agreement with Dexcom (Nasdaq:DXCM) to settle all ...

A pickleball player wears the Stelo over-the-counter CGM. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) announced today that it launched a proprietary generative AI platform integrated with its ...

The Vivani NanoPortal technology. [Image courtesy of Vivani] Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant.

The FDA has issued a warning letter related to BD Pyxis automated medication dispensing systems — technology that was part of its $12 billion CareFusion acquisition in 2015. The warning letter, dated ...

Qnovia’s nicotine replacement therapy device. [Image courtesy of Qnovia] Qnovia announced that it raised $16 million in Series B funding to support its inhaled smoking cessation therapy platform. Blue ...

The Eversense 365 long-term implantable CGM. [Image courtesy of Senseonics/Ascensia] Senseonics (NYSE:SENS) today announced significant progress with the launch of its Eversense 365 continuous glucose ...

A person uses Afrezza inhaled insulin powder. [Image courtesy of MannKind] MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.